SCHEMBL6774085

SCHEMBL6774085

O=c1ccc2cc(SCl)ccc2o1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 6/20 0.56
CA9 Q16790 6/20 0.56
MCL1 Q07820 4/20 0.56
ALDH1A1 P00352 3/20 0.56
LMNA P02545 3/20 0.53
CYP3A4 P08684 3/20 0.53
HSD17B10 Q99714 3/20 0.53
CYP1A2 P05177 2/20 0.53
MAPT P10636 2/20 0.53
HPGD P15428 2/20 0.53
ALOX15 P16050 2/20 0.53
HIF1A Q16665 2/20 0.53
TDP1 Q9NUW8 2/20 0.53
CYP2D6 P10635 2/20 0.53
CYP2C19 P33261 2/20 0.53
MEN1 O00255 1/20 0.53
GMNN O75496 1/20 0.53
TP53 P04637 1/20 0.53
TSHR P16473 1/20 0.53
MAPK1 P28482 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3086551 0.76 CA12 (0.60) CA12CA9MCL1ALDH1A1LMNA
SCHEMBL28620191 0.74 CA12 (0.58) CA12CA9MCL1ALDH1A1LMNA
SCHEMBL5542275 0.74 CA12 (0.62) CA12CA9MCL1ALDH1A1LMNA
SCHEMBL29412607 0.72 ALDH1A1 (1.00) CA12CA9MCL1ALDH1A1LMNA
6-Hydroxycoumarin SCHEMBL30640534 0.72 CA12 (1.00) CA12CA9MCL1ALDH1A1LMNA
SCHEMBL29441432 0.72 CA12 (0.60) CA12CA9MCL1ALDH1A1LMNA
SCHEMBL194842 0.72 ALDH1A1 (1.00) CA12CA9MCL1ALDH1A1LMNA
6-Hydroxycoumarin SCHEMBL187709 0.72 CA12 (1.00) CA12CA9MCL1ALDH1A1LMNA
SCHEMBL16410056 0.72 CA12 (0.60) CA12CA9MCL1ALDH1A1LMNA
SCHEMBL875198 0.72 CA12 (0.60) CA12CA9MCL1ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP disclosed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO disclosed